As of September 30, 2025 and December 31, 2024, the Company has $126,275 due from Viral Gene included in due from Gene. The Company's CEO is also the CEO of Viral Gene. The loan does not bear any interest. classified as current in the accompanying unaudited condensed consolidated balance sheets. All of the loans are with related As the Company's loans are with related parties, the Company and its related parties have mutually agreed to defer repayment until a time that is mutually agreed upon between the Company and its related parties. Accordingly, none of these In connection with the Business Company, the Company's certificate of incorporation was amended and restated to designate two classes of stock; preferred and common stock. The certificate of incorporation authorized 1,00o,000 shares of preferred stock authority to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. expressed in such resolutions. There were zero preferred shares outstanding as of September 30, 2025 and December 31, 2024. https://www.sec.gov/Archives/edgar/data/1971387/000110465926012942/limn-20250930xs1.htm